Severity |
Management |
Mild |
I&Da |
Moderate |
– I&D and antibiotic therapy – Empiric treatment options: 1) Cephalexin if there is low risk for MRSA or confirmed MSSA 2) TMP/SMX 3) Doxycycline 4) Clindamycinb – If polymicrobial coverage is required (eg, perioral/perirectal abscess, penetrating trauma): amoxicillin/clavulanate ± doxycycline/SMX-TMP (if there are concerns for MRSA) |
Severe |
– I&D and antibiotic therapy – Empiric treatment options: one of vancomycin, daptomycinc, or linezolidc and One of the following combinations: 1) Piperacillin/tazobactamd 2) Ciprofloxacin and metronidazoled 3) Ceftriaxone and metronidazolee – Adjust treatment options based on susceptibilities |
a Oral antibiotics with activity against Staphylococcus aureus can be considered in case of extensive surrounding cellulitis, immunocompromised state, inadequate response to I&D alone (with good source control), abscess size >2 cm. b Clindamycin may be considered if clindamycin local resistance is <10%-15% and/or there are other compelling indications. It should be avoided as a first-line option. c Consultation with infectious diseases is recommended prior to initiation of these agents. d Review local antibiogram data if this combination is being used for coverage of Pseudomonas aeruginosa. e If the patient has risk factors for P aeruginosa infection, this combination would not provide adequate coverage. |
|
I&D, incision and drainage; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; TMP/SMX, trimethoprim/sulfamethoxazole. |